GRAFORCE
24.1.2023 19:01:49 CET | Business Wire | Press release
Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Kawasaki Gas Turbine Europe GmbH (Kawasaki), a European gas turbine and heat-power cogeneration business, are cooperating for zero-emission heat and power generation. The joint innovative plant concept combines Graforce's methane electrolysis technology (plasmalysis) with hydrogen turbines from Kawasaki. First customer projects for this zero carbon heat and power solution are in the works.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230123005010/en/
Hydrogen turbines and methane electrolysis are game changers for an electricity-independent zero carbon heat-power cogeneration. (Photo: Business Wire)
“Our joint zero-emission plant is a breakthrough for the decarbonization of both, fossil fuels and manufacturing industries”, explains Dr. Jens Hanke, CTO of Graforce. “This technology generates CO2-free high-temperature heat via hydrogen, the carbon black is used as a raw material in production, and – best of all, the process is self-sufficient and does not need further electricity after having been started. This in turn relieves the strain on power grids.”
Decarbonization of industrial processes
The new plant solution generates hydrogen from biomethane, natural gas, LNG or LPG by methane electrolysis technology. The hydrocarbons will remain the initial source, but instead of being burnt, a high frequency plasma splits the hydrocarbons into CO2-free hydrogen and carbon black.
The hydrogen is converted to electricity in Kawasaki's hydrogen gas turbine and reused for hydrogen production in the plasma electrolyzer. The ultra-high temperature CO2-free exhaust gas from the hydrogen gas turbine can be used in production processes in various industries. Companies that previously generated high-temperature heat with natural gas can significantly increase their overall efficiency while reducing their gas and especially electricity costs.
Carbon black is used as a synthetic raw material for industrial production. This way, CO2 can be sequestered long-term in steel, cement or for soil enhancement. For industries which require both high temperatures and large quantities of carbon black for production this process pays off twice – in terms of climate protection and cost-effectiveness.
Beyond industry, this hydrogen-based heat-power cogeneration plant can be used for CO2-free heating in surrounding urban areas.
Both technologies were awarded with the Innovation Award of the German Gas Industry, in 2020 and 2022.
About
Kawasaki Gas Turbine Europe GmbH
The German company, 100% subsidiary of Kawasaki Heavy Industries, LTD. (Japan), providing natural gas and hydrogen gas turbine generator set to improve the energy efficiency for various industries and to contribute the global environmental conservation. http://www.kawasaki-gasturbine.de/en
Graforce GmbH
Graforce is German hydrogen technology company developing and manufacturing Power-to-X plants to decarbonize fossil energies, industrial sectors and the heat, transport and building sectors. The company is currently in a process to expand its strategic partnerships with financial as well as strategic investors to quickly scale its hydrogen technology worldwide. www.graforce.com/EN
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom